红细胞生成素大剂量冲击维持疗法治疗血液肿瘤贫血的临床研究.docVIP

红细胞生成素大剂量冲击维持疗法治疗血液肿瘤贫血的临床研究 红细胞生成素大剂量冲击维持疗法治疗血液肿瘤贫血的临床研究 郑暹雄陈俊贤陈荣庆 普市人民医院』东普宁515300 摘要目的研究红细胞生成素(EP0)大剂量冲击维持疗法治疗血液肿瘤贫血患者的临床疗效和安全性.方法采用 开放性非随机的临床研究方法,恶性血液肿瘤患者在化疗同时,于第1周采用EPO120,000u冲击用药(40,000u皮下 d1,d3,d5),随后EPO每周40,000U皮下(d8,dl5,d22)维持用药,共4周.比较治疗前后每周的血红蛋白(Hb)和 红细胞压积(Hct)水平,并评价EPO治疗的不良反应.蛄果2003年10月一2005年12月共入纽42例同期化疗的血液肿 瘤贫血患者.所有患者给予EP0治疗后Hb水平呈持续上升趋势,在治疗后第2,4周Hb比治疗前上升gt;2.0g/dl的患者分 别占26.8%和52.6%.在治疗后第2,4周Hb的平均值分别为85.6g/dl和92.8g/dl,与治疗前相比均具有显着性差异(P (O.O5).治疗前后平均Hct值亦有显着性差异(Plt;O.05).所有使用EPO大剂量冲击维持疗法治疗的患者均耐受良好.蛄 论血液肿瘤贫血患者使用EPO大剂量冲击维持疗法,可有效改善惠者的贫血状况,且使用安全,耐受良好 关键词血液肿瘤贫血治疗红细胞生成素 CIinicaIStudyofInductionhighclosetherapyfoIIowedbyMain— tenancewithEPOinAnemicHematoIogicaIMaIignancyPatients AbstractObjectiveAnemiaisacommoncomplicationofhematologicalma1ignancy.AndtheuseofEPOhas beenprovedtoimprovethecomplaintsofpatientswithcaneer—re1atedanemia.Yhisstudyistodetermine whetherinductionhighdoseEPOfollowedbyweeklymaintenanceusagecouldimprovehemoglobin(Hb)1evels inanemichemato]ogicalma1ignancypatientsreceivingchemotherapy.MethodsTheopen—labe1.n0nrand0mized c1inicalstudyeva1uatedtheresponserateofinductionEPO120,000U(40,000USCd1,d3,d5)fol1owed bymaintenancedoseof40,000USConceweeklyfor3weeks(d8,d15,d22).MeanHemoglobinandHctwere measuredpretreatmentandweeklYduringthetreatment.ResultsFromOct.2003toDec.2005,42cancer～ relatedanemichematologicalmalignancypatientsreceivingconcurrentchemotherapywereaccrued.Mean hemoglobinandHctkeptincreasingduringthetreatment.andthepercentagethathemoglobin≥2.Og/dl increasecomparedwithpretreatment(69.5g/d1)inweek2(n=41)andweek4(n=38)are26,8%and52.6%respectively. Meanhemoglobinatweek2andweek4are85.6g/dland92.8g/d1respectively,andsignificantlyhigherthan pretreatment(O.05).A¨patientsacceptingthistreatmentwerewel1tolerant.ConclusionInduction highdosetherapyfol1owedbymaintenancewithEPOcanimprovehemoglobinandHctincancer—relatedanemic hemat01Ogica1ma]ignancypatjentsundergoingchemotherapywith1imitedadverseeffects. KeywordsCancerAnemiaTreatmentEpo 中图分类号:R552文献标识码:A文章